HIVAIDS communities and AIDS vaccine research AIDES TRT5

HIV/AIDS communities and AIDS vaccine research AIDES / TRT-5 Tour Essor 14, rue Scandicci 93508 Pantin Cedex

Questions from the community o o ANRS and vaccine trials of therapeutic vaccines ANRS and recruitment of HIVvolunteers to participate to vaccine trials (safety issues raised) Partnership with African NGOs (Réseau Afrique 2000): how far are we from a vaccine? To stop the spread of AIDS

To be better informed o TRT-5 first met n n o o with the ANRS investigators (1999) Aventis (Alvac) in 1999 Attendance to scientific meetings Internal training sessions (immunologists)

To inform (articles in our newsletters)

To inform (training sessions in Africa)

To inform (symposium on immunology)

To inform o o Press releases after the announcement of the results of the ANRS trials Press release after AIDSVAX results

To link up o Vaccine Working Group o IAVI partnership o Microbicides initiative

To work with o ANRS n n AC 5 Clinical trials: to have two community representatives (voting rights) AC 28 Preventive vaccines: two community representatives (one from the HIV community and one from the volunteers) o o Modification of design of clinical trials Set up of the long term follow up of vaccinees

To lobby o o o Towards the Industry to have access to vaccine preparation (Aventis supplied Orvéac with ALVAC after a TRT-5 meeting) Authorities to maintain a strong commitment to prolong the ANRS Within the ANRS, AC 28 to finally do a proper work!

To lobby o o o Within our organization for preventive technologies to be a priority EU for commitment French government to pursue funding for a preventive vaccine. Does it have to be only directed to the ANRS?